Drug intelligence / Profile preview

Embold Therapeutics neurodegeneration program

Development stage: Unknown
Lead developer: Embold Therapeutics

Overview

This discovery-stage program is being developed by Embold Therapeutics for the treatment of neurodegenerative diseases. As of early 2024, the specific molecular target and therapeutic modality remain confidential. The program is part of the company's broader pipeline focused on addressing proteinopathies and lysosomal dysfunction, often utilizing an AI-optimized enzyme approach to improve the properties of therapeutic enzymes. This candidate is currently in the early discovery phase, following the company's lead program, EMB-014, which targets GCase for Parkinson's disease.

Other names: otherEmbold Therapeutics-confidential-neurodegeneration

Targets

GBA1 (Glucosylceramidase)

Beyond the preview

Go deeper on Embold Therapeutics neurodegeneration program.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Embold Therapeutics neurodegeneration program.

Explore the full profile